Why has the NIB share price leapt 14% in a month?

NIB shares have been in fine form recently…

| More on:
A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Limited (ASX: NHF) share price has been a strong performer in recent weeks.

Since this time last month, the private health insurer's shares have risen by almost 14% to $7.89.

This leaves the NIB share price trading within a whisker of its 52-week high of $8.20.

Why is the NIB share price on form?

Investors have been buying the company's shares since the release of its full year results last month.

For the 12 months ended 30 June, NIB reported a 7.2% increase in revenue to $2.8 billion. This was driven by the company's Australian Residents Health Insurance (ARHI) business, which grew well ahead of industry expectations thanks to strong premium revenue growth. This was despite the company deferring the 2022 annual premium increase.

And while NIB reported a 16.6% decline in net profit to $133.8 million, this reflects investment losses of $81.8 million and was still slightly ahead of consensus estimates.

Also giving its shares a lift was management's outlook commentary. It appears cautiously optimistic on FY 2023. It said:

While wary of broader macro-economic conditions and ongoing COVID-19 threats, nib expects favourable market conditions for each of its businesses in FY23 and beyond.

Can its shares keep rising?

Unfortunately, most brokers appear to believe the NIB share price has now peaked.

The most bullish broker I'm aware of is Morgans with its hold rating and $8.36 price target. This implies potential upside of 6% for investors from current levels.

Its analysts are also expecting its shares to provide a fully franked 3.5% dividend yield in FY 2023. This stretches the total potential return to almost 10%, which isn't bad for a hold rating.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »